[HTML][HTML] An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen
M Limonta-Fernández, G Chinea-Santiago… - New …, 2022 - Elsevier
Developing affordable and easily manufactured SARS-CoV-2 vaccines will be essential to
achieve worldwide vaccine coverage and long-term control of the COVID-19 pandemic …
achieve worldwide vaccine coverage and long-term control of the COVID-19 pandemic …
Advancements in the preparation technology of small molecule artificial antigens and their specific antibodies: a comprehensive review
Y Chen, S Ma, M Zhou, Y Yao, X Gao, X Fan, G Wu - Analyst, 2024 - pubs.rsc.org
Small molecules find extensive application in medicine, food safety, and environmental
studies, particularly in biomedicine. Immunoassay technology, leveraging the specific …
studies, particularly in biomedicine. Immunoassay technology, leveraging the specific …
Development of a scalable single process for producing SARS-CoV-2 RBD monomer and dimer vaccine antigens
T Boggiano-Ayo, J Palacios-Oliva… - … in Bioengineering and …, 2023 - frontiersin.org
We have developed a single process for producing two key COVID-19 vaccine antigens:
SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are …
SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are …
A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune …
L Lazo, M Bequet-Romero, G Lemos, A Musacchio… - Vaccine, 2022 - Elsevier
Since the beginning of the COVID-19 pandemic, the development of effective vaccines
against this pathogen has been a priority for the scientific community. Several strategies …
against this pathogen has been a priority for the scientific community. Several strategies …
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of …
Subunit vaccines based on the receptor-binding domain (RBD) of the spike protein of SARS-
CoV-2 provide one of the most promising strategies to fight the COVID-19 pandemic. The …
CoV-2 provide one of the most promising strategies to fight the COVID-19 pandemic. The …
Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein …
Coronavirus disease 2019 (COVID-19) has caused the ongoing COVID-19 pandemic and
there is a growing demand for safe and effective vaccines. The thermophilic …
there is a growing demand for safe and effective vaccines. The thermophilic …
Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against …
R Nechooshtan, S Ehrlich, M Vitikainen, A Makovitzki… - Vaccines, 2022 - mdpi.com
SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and
virulence. The original and mutant viruses escape host innate (Interferon) immunity and …
virulence. The original and mutant viruses escape host innate (Interferon) immunity and …
Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells
G Gerez, J Martinez, C Steinbrugger, S Bouanich… - Biomolecules, 2022 - mdpi.com
SARS-CoV-2 receptor-binding domain (RBD) is a major target for the development of
diagnostics, vaccines and therapeutics directed against COVID-19. Important efforts have …
diagnostics, vaccines and therapeutics directed against COVID-19. Important efforts have …
Chimeric antigen by the fusion of SARS-CoV-2 receptor binding domain with the extracellular domain of human CD154: A promising improved vaccine candidate
I Ávalos, T Lao, EM Rodríguez, Y Zamora, A Rodríguez… - Vaccines, 2022 - mdpi.com
COVID-19 is a respiratory viral disease caused by a new coronavirus called SARS-CoV-2.
This disease has spread rapidly worldwide with a high rate of morbidity and mortality. The …
This disease has spread rapidly worldwide with a high rate of morbidity and mortality. The …
The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines
G Keresztes, M Baer, MR Alfenito, TC Verwoerd… - Vaccines, 2022 - mdpi.com
(1) Influenza viruses constantly change and evade prior immune responses, forcing
seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine …
seasonal re-vaccinations with updated vaccines. Current FDA-approved vaccine …